Amgen Inc. $AMGN Shares Purchased by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 12.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 59,661 shares of the medical research company’s stock after buying an additional 6,705 shares during the quarter. Amgen comprises about 1.1% of Foster Victor Wealth Advisors LLC’s holdings, making the stock its 27th largest position. Foster Victor Wealth Advisors LLC’s holdings in Amgen were worth $17,772,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Amgen in the first quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its position in Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85 shares during the period. Legacy Investment Solutions LLC purchased a new stake in Amgen in the 2nd quarter valued at approximately $27,000. Activest Wealth Management boosted its holdings in Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 103 shares in the last quarter. Finally, Evelyn Partners Investment Management LLP acquired a new position in Amgen during the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 10,908 shares of company stock valued at $3,674,966 over the last quarter. Corporate insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Daiwa Capital Markets raised their price target on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. BMO Capital Markets upped their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. DZ Bank raised their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Morgan Stanley decreased their target price on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $332.85.

Amgen Stock Up 0.9%

AMGN opened at $327.38 on Friday. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The company has a market cap of $176.29 billion, a price-to-earnings ratio of 25.30, a PEG ratio of 2.96 and a beta of 0.45. Amgen Inc. has a one year low of $257.05 and a one year high of $346.38. The business’s fifty day moving average is $319.32 and its two-hundred day moving average is $300.20.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter last year, the business posted $5.58 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.